Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols

Protocols

EDRN investigators protocols. The following is a list of the EDRN protocols that have been captured and curated. Additional information will be added as it is available. Contact information is provided as part of the detail for each protocol.

Contents

Title Abstract Investigator
Clinical Proteomic Technologies for Cancer Initiative (CPTAC) Phase I CPTAC Phase I 2006 - 2011, was developed to address the pre-analytical and analytical variability issues that are major barriers to the field of proteomics. ... Kinsinger, Chris
Clinical Proteomic Technologies for Cancer Initiative (CPTAC) Phase II The objective of the "System Suitability (CompRef) Study" was to validate mass spectrometry protocols used at each Proteome Characterization Center (PCC). Kinsinger, Chris
Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection Tumor-associated stromal cells differ from normal gland-associated stromal cells in gene expression. Genes up-regulated in these stromal cells are potential ... Liu, Alvin Y.
Clinical Validation of Molecular Signatures of Cervical Neoplasia Unger, Elizabeth R.
Clinical and Analytical Validation of Cancer Biomarkers: Developmental Studies Chan, Daniel
Clinical validation of an autoantibody test for lung cancer BACKGROUND: Autoantibodies may be present in a variety of underlying cancers several years before tumours can be detected and testing for their presence may ... Boyle, Peter
Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Identification of molecular markers often leads to important clinical applications such as early diagnosis, prognosis, and drug targeting. Lung cancer, the ... Kim, Bumjin
Collaborative study on SELDI biomarker discovery and serum protein profiling of lung cancers Semmes, John
Colon Cancer Specimen Reference Set Application: Disis - University of Washington (2008) The proposed study aims to validate the diagnostic value of a panel of serum antibodies for the early detection of colorectal cancer (CRC). We have developed a ... Disis, Mary L
Colon Cancer Specimen Reference Set Application: Getzenberg - Johns Hopkins (2008) The goal of this project is to confirm the early validation of CCSA-3 and CCSA-4 as biomarkers for the early detection of adenocarcinoma of the colon and ... Getzenberg, Robert H.
Colon Cancer Specimen Reference Set Application: Jendoubi - Milagen (2006) No Data Received at DMCC Jendoubi, Moncef
Colon Cancer Specimen Reference Set Application: Kim - DiaDexus (2008) Kim, Nam
DCIS Team Project This procedure applies to identification of the cohort and of cases and controls from the cohort of women with the diagnosis of DCIS at the Seattle CVC (PI= ... Li, Christopher
DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. We used MethyLight assays to analyze DNA methylation status of 27 genes on 49 paired cancerous and noncancerous tissue samples from non-small cell lung cancer ... Feng, Qinghua
Depo-Provera and Breast Cancer: Epidemiology/Pathology The injectable contraceptive depot medroxy-progesterone acetate (DMPA) (Depo-Provera) is commonly used by women worldwide, and it contains the same progestin ... Li, Christopher
Detecting Breast Cancer Signatures in Body Fluids Trock, Bruce
Detecting breast cancer protein signatures in body fluid Semmes, John
Detection of Bladder CA by Microsatellite Analysis (MSA) Goal 1: To determine sensitivity and specificity of microsatellite analysis (MSA) of urine sediment, using a panel of 15 microsatellite markers, in detecting ... Schoenberg, Mark P.
Detection of Serum Markers of Breast Cancer by SELDI Marks, Jeffrey
Detection of Serum Proteomic Patterns and SNPs in Breast Cancer: A Pilot Study Esserman, Laura J.
Detection of cancer DNA markers in urine Block, Timothy
Development and Clinical Validation of Biomarkers for Prostate Cancer Partin, Alan W
Development and Evaluation of a Tumor Marker for Prostate Cancer Major strides in the early detection, staging, monitoring, and risk stratification of men with prostate cancer have been realized over the last few decades. ... Partin, Alan W
Development of FISH-based assay for early detection of high grade cervical dysplasia Unger, Elizabeth R.
Development of a magneto-nanosensor (MNS) array for prostate cancer biomarkers Our goal is to develop a blood-based biomarker magneto-nanosensor array for the accurate early detection and prognostication of prostate cancer Gambhir, Sanjiv
Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. PURPOSE: Non-small cell lung cancer (NSCLC) has an overall 5-year survival of <15%; however, the 5-year survival for stage I disease is over 50%. ... Farlow, Erin C.
Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer PURPOSE: To select autoantibody signatures as noninvasive biomarkers of non-small cell lung cancer (NSCLC). EXPERIMENTAL DESIGN: A phage cDNA expression ... Wu, Lingling
Development of paraffin-based expression profiles to predict minimal vs. substantial risk of disease progression using retrospective datasets Esserman, Laura J.
Dubinett - Targeted Sequencing 2012 we propose to use targeted massively parallel DNA sequencing to identify somatic alterations within mutational hotspots in matched sets of primary lung tumors, ... Dubinett, Steve
EDRN Biomarker Reference Lab: Pacific Northwest National Laboratory The purpose of this project is to develop antibody microarrays incorporating three major improvements compared to previous antibody microarray platforms, and ... Rodland, Karin
2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.